

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Antengene Corporation Limited**

**德琪醫藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 6996)**

### **VOLUNTARY ANNOUNCEMENT INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE**

This announcement is made by the Company on a voluntary basis. Reference is made to the Company's voluntary announcement dated April 8, 2025 in relation to its proposed share repurchase (the "**Announcement**"). Capitalised terms used in this announcement shall have the same meanings as defined in the Announcement unless the context requires otherwise.

Since the Company announced its intention to conduct the one-market share repurchase on April 8, 2025 and up to the date of this announcement, the Company has not repurchased any of its Shares. Pursuant to the relevant resolutions passed at the annual general meeting of the Company held on June 13, 2025 (the "**AGM**"), the directors of the Company have been granted powers under a general mandate to repurchase up to 67,944,663 shares of the Company (the "**Shares**"), representing 10% of the total number of the issued Shares as at the date of the AGM (the "**Proposed Share Repurchase**").

On August 29, 2025, the Board resolved to approve the proposed exercise of its powers under the Share Repurchase Mandate and, subject to market conditions, to repurchase Shares in the open market from time to time at a maximum aggregate price of HK\$40 million. The Company will conduct the Proposed Share Repurchase in compliance with the articles of association of the Company, the Listing Rules, the Codes on Takeovers and Mergers and Share Buy-backs, the Companies Act (as revised) of the Cayman Islands and all applicable laws and regulations to which the Company is subject. The Board will determine whether the repurchased Shares will subsequently be cancelled or held by the Company as treasury shares, subject to market conditions and the capital management needs of the Group at the relevant time of the repurchases.

The Company will finance the Proposed Share Repurchase by its internal resources.

The Board believes that a share repurchase in the present conditions will demonstrate the Company's confidence in its own business outlook and prospects and would, ultimately, benefit the Company and create value to the Shareholders. The Board believes that the current financial resources of the Company would enable it to implement the Proposed Share Repurchase while maintaining a solid financial position. The Board considers that the Proposed Share Repurchase is in the best interest of the Company and its Shareholders as a whole.

As of the date of this announcement, the Company has not repurchased any of its Shares.

**Shareholders and potential investors should note that the implementation of the Proposed Share Repurchase by the Company will be subject to market conditions and at the Board's absolute discretion. There is no assurance of the timing, quantity or price of any repurchase, or whether the Company will make any repurchase at all. Shareholders and potential investors should therefore exercise caution when dealing in the Shares.**

By Order of the Board  
**Antengene Corporation Limited**  
**Dr. Jay Mei**  
*Chairman*

Hong Kong, September 1, 2025

*As at the date of this announcement, the board of directors comprises Dr. Jay Mei and Mr. Donald A. Lung as executive Directors; and Ms. Jing Qian, Mr. Sheng Tang and Dr. Rafael Fonseca as independent non-executive Directors.*

## About Antengene

Antengene Corporation Limited (“**Antengene**”, SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor).

Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring “2+1” bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune disease, solid tumors and hematological malignancies indications.

To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is approved in the Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia.

## Forward-looking statements

The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this announcement. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange.